Navigation Links
Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine

Inc. "The ability to quickly titrate patients to the optimal dose will be an important competitive strength for our product in the marketplace."

The poster will be available on Labopharm's web site (www.labopharm.com) on Monday, July 2, 2007 following conclusion of the Forum.

In addition, representatives of the Company will be at Labopharm's corporate booth to promote its once-daily tramadol product to medical professionals from around the world, as well as to generate awareness of Labopharm's drug optimization technologies.

Labopharm also announced today that an article discussing the Company's study to characterize the pharmacokinetics and to assess the dose proportionality of 100 mg, 200 mg and 300 mg strengths of its once-daily formulation of tramadol will be published in the September 2007 edition of the journal Biopharmaceutics and Drug Disposition (Volume 28, Issue 6, Pages 323-330). An advanced online version of the article is available now at http://www3.interscience.wiley.com/cgi-bin/jissue/114204607 (pay-per-view basis, fee of US$25).

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company has a robust pipeline of follow-on products in both pre-clinical and clinical development. For more information, please visit www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially fro
'"/>




Page: 1 2 3

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... report is available in its catalogue: ... and Technologies for Advanced Drug Delivery ... Administration http://www.reportlinker.com/p01941928/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-Routes-of-Administration.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... scientists increasingly are applying genomics technologies to toxicology research ... on a variety of organ systems, reports Genetic ... are especially interested in figuring out a new compound,s ... technique, according to the November 15 issue of ...
... LONDON, November 19 NeuroDiscovery Ltd (ASX:,NDL), ... development Company,and Sosei Group Corporation ("Sosei"; TSE ... today announce that NeuroSolutions,is presenting further pivotal ... is a potential therapy for neuropathic pain ...
Cached Medicine Technology:GEN Reports on the Trend Toward Predictive Toxicogenomics 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3
(Date:4/20/2014)... single type of cell in the lining of the ... cancer, according to researchers at the Stanford University School ... the first to pinpoint the normal cell type that ... the first to show that most bladder cancers and ... and explains why many human bladder cancers recur after ...
(Date:4/18/2014)... article published online in The Gerontologist ... music is associated with a decrease in anxiety about ... of control over their lives. In particular, listening to ... about death and an increase in sense of control. ... women and men, and individuals of both low- and ...
(Date:4/18/2014)... What,s one of your worst memories? How did it ... felt during a negative personal experience, such as how ... lead to emotional distress, especially when you can,t stop ... creep up, thinking about the context of the memories, ... and effective way to alleviate the negative effects of ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/17/2014)... PHILADELPHIA The presence of chronic inflammation in ... aggressive, prostate cancer, and this association was found ... levels, according to a study published in ... of the American Association for Cancer Research. , ... some participants of the placebo arm of the ...
Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Religious music brings benefit to seniors' mental health 2Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New research shows people are thinking about their health early in the week 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... Exam in Their List of New Year,s Resolutions ... Improvement in Their Visual Acuity, PINELLAS PARK, Fla., Dec. 27 ... of top five New Year,s resolutions could,obtain better visual acuity and ... most common New Year,s resolutions may be to lose,weight, exercise more ...
... first nationwide clinical study showing the benefits of an ... the Dec. 27 issue of the New England Journal ... the biggest improvement in metastatic breast cancer ever reported ... time between initiation of chemotherapy for metastatic disease and ...
... Dec. 27 Computer Sciences,Corporation (NYSE: ... signed an extension to,a global information technology ... Inc., Under the five-year agreement, CSC ... support services for Sun,s business,applications portfolios -- ...
... FDA -, MENLO PARK, Calif., Dec. 27 ... drug-eluting stent (DES),systems, today announced that it has submitted ... Mark approval of its Custom NX DES,System., XTENT,s ... the,drug formulation submission from Biosensors International Group. XTENT,plans to ...
... Dec. 26 Whether it,s living and dying with,every ... the nachos and pizza,that make up the game watching ... of heartburn. Prilosec OTC, the number one selling OTC,heartburn ... opportunity to,win tickets to Super Bowl forty-two in Glendale, ...
... promising, they don,t address benefits of drug therapy , , ... wipes out abnormal heart tissue reduces the number of ... heart attacks, a new trial showed. , While those ... into abnormal rhythms, they are desirable to avoid not ...
Cached Medicine News:Health News:A New Kind of New Year's Resolution Could Bring Clarity to Americans 2Health News:A New Kind of New Year's Resolution Could Bring Clarity to Americans 3Health News:Taxol with avastin produces noteworthy results 2Health News:CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 3Health News:Heart Procedure Reduces Need for Defibrillator Shocks 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 3
The Mikro 20 line of centrifuges has 4 models for microlitre applications complete with rotor. Whether cryo, PCR or standard micro tubes, it is the appropriate centrifuge of choice with angle rotor....
... random access operation, the Elecsys 2010 System ... volume laboratories that want to maximize productivity ... flexibility and Stat capabilities of the Elecsys ... to the changing needs of an aggressive ...
... Dimension Xpand integrated chemistry system ... compact footprint to the smaller ... and integration, the Dimension Xpand ... Dimension technology, specifically tailored for ...
The Dimension RxL Max is an integrated chemistry system and is the most powerful and technologically advanced Dimension analyze with new standard for excellence in clinical diagnostics. Simply put, t...
Medicine Products: